非アルコール性脂肪性肝疾患(NAFLD)・NASHの世界市場2021年-2031年

◆英語タイトル:Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031

visiongainが発行した調査報告書(VGA21MA023)◆商品コード:VGA21MA023
◆発行会社(リサーチ会社):visiongain
◆発行日:2021年2月
◆ページ数:338
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)USD4,549 ⇒換算¥673,252見積依頼/購入/質問フォーム
Global Site License(法人閲覧用、1年間、印刷可)USD9,099 ⇒換算¥1,346,652見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートでは、世界の非アルコール性脂肪性肝疾患(NAFLD)・NASHの世界市場について調査・分析し、レポート概要、エグゼクティブサマリー、産業概要、市場の推進力・制約・機会、市場動向、疾患原因別分析、薬剤種類別分析、販売チャネル別分析、地域別分析などの項目を掲載しています。
・レポート概要
・エグゼクティブサマリー
・産業概要
・市場の推進力・制約・機会
・市場動向
・世界の非アルコール性脂肪性肝疾患(NAFLD)・NASH市場規模:疾患原因別
・世界の非アルコール性脂肪性肝疾患(NAFLD)・NASH市場規模:薬剤種類別
・世界の非アルコール性脂肪性肝疾患(NAFLD)・NASH市場規模:販売チャネル別
・世界の非アルコール性脂肪性肝疾患(NAFLD)・NASH市場規模:地域別
・主要企業情報

What is holding you back in the Non-alcoholic Fatty Liver Disease & NASH Business?

NASH is presently diagnosed by methods such as blood test, imaging or a liver biopsy. These tests are time consuming and have less certainty as they are generic tests. Imaging techniques like CT, MRI and Ultrasound scans were inaccurate to diagnose NASH. These tests are not just incorrect for NASH diagnosis but also cost a lot. This absence of conclusive diagnostic methods in order to detect NASH, is the major challenge to the NASH market.

Our 330+ page report provides 275 tables, 191 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing non-alcoholic fatty liver disease & NASH market. Buy our report to see how to exploit these opportunities in the global market.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.
Discover sales predictions for the global non-alcoholic fatty liver disease & NASH market and submarkets

Along with revenue prediction for the overall world market, there are 5 segmentations of the non-alcoholic fatty liver disease & NASH market, with forecasts for 5 Disease Cause, 5 Drug Types, 3 Types, 4 Sales Channel each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth

As per Visiongain analysis, global non-alcoholic fatty liver disease & NASH market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

What all Segments Are Covered in the Report?

Global Non-alcoholic Fatty Liver Disease & NASH Market by Disease Cause (COVID-19 Impact Recovery Analysis Covered)
• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity
• Other Disease Causes
Global Non-alcoholic Fatty Liver Disease & NASH Market by Drug Type (COVID-19 Impact Recovery Analysis Covered)
• Vitamin E & Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib
• Cencicriviroc
• Other Drug Type
Global Non-alcoholic Fatty Liver Disease & NASH Market by Sales Channel (COVID-19 Impact Recovery Analysis Covered)
• Hospital Pharmacy
• Online Suppliers
• Retail Pharmacy
• Other Sales Channel
Global Non-alcoholic Fatty Liver Disease & NASH Market by Region (COVID-19 Impact Recovery Analysis Covered)
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa
Need industry data? Please contact us today.

Which Key Players Are Leading the Global Market and how much Share do they Hold?

The global market for non-alcoholic fatty liver disease & NASH is ascending and has made significant gains in NASH treatments. The players in the non-alcoholic fatty liver disease & NASH market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
• Mergers and acquisitions.
• Product launches.
• Collaborations and partnerships.
Product approval is a major milestone facing all key competitors in the non-alcoholic fatty liver disease & NASH market. Several strategies were implemented by key market players between 2015 and Jan 2021. There are over 100 pharma companies involved in different aspects of NASH therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.

How the Non-alcoholic Fatty Liver Disease & NASH Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated
• What is the current size of the overall global non-alcoholic fatty liver disease & NASH market? How much will this market be worth from 2021 to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are some of the most prominent human non-alcoholic fatty liver disease & NASH currently in development?
• What are the main trends that will affect the world non-alcoholic fatty liver disease & NASH market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global non-alcoholic fatty liver disease & NASH market evolve over the forecasted period, 2021 to 2031?
• Which NASH drugs and therapies can succeed and what revenues could they generate to 2031?
• What will be the main commercial drivers for the NASH market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?
Top 20 Leading Players Profiled in the Report
• Pfizer Inc. (Pfizer)
• Roche Holding AG (Roche)
• Takeda Pharmaceutical Company Limited
• Intercept Pharmaceuticals, Inc.
• AstraZeneca PLC
• Novartis AG
• Merck & Co., Inc.
• AbbVie Inc. (AbbVie)
• Gilead Sciences, Inc.
• Genfit Biotechnology
• Cardax, Inc.
• Daewoong Co Ltd
• Madrigal Pharmaceuticals, Inc.,
• Mirum Pharmaceuticals, Inc.
• GW Pharmaceuticals plc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

❖ レポートの目次 ❖

1. Report Overview
1.1 Introduction to Non-alcoholic Fatty Liver Disease & NASH Market
1.2 Non-alcoholic Fatty Liver Disease & NASH Market Definition
1.3 Global Market Overview
1.4 Why You Should Read This Report
1.5 What This Report Delivers
1.6 Key Questions Answered By This Analytical Report Include:
1.7 Who is This Report For?
1.8 Methodology
1.8.1 Primary Research
1.8.2 Secondary Research
1.8.3 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQs)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2 Executive Summary
2.1 Key Highlights
3 Non-alcoholic Fatty Liver Disease & NASH Industry Overview
3.1 Overview
3.1.1 Risk Factors for NAFLD & NASH
3.1.2 Diagnosis and Staging of NAFLD/NASH
3.1.3 Imaging Assessment of Steatosis
3.1.4 Liver biopsy for NAFLD
3.1.5 A Pragmatic Approach To Diagnosis And Staging Of NAFLD In Clinical Practice
3.2 COVID-19 Impact of Liver Diseases
4 Market Drivers, Restraints and Opportunities
4.1 Overview
4.2 Increase in number of patients affected by NASH
4.3 Rising Healthcare Expenditure
4.4 Rising Studies And Drugs Developments
4.5 Absence Of Low-Cost And Definitive Diagnostic Methods
4.6 Challenge Due To Regulatory Bodies And Drug Approval
4.7 Porter’s Five Forces Analysis
4.7.1 Threat of New Entrants – Low
4.7.2 Bargaining Power of Suppliers – Low
4.7.3 Bargaining Power of Buyers – Moderate
4.7.4 Threat of Substitutes – Moderate to Low
4.7.5 Competitive Rivalry – High
5 Global Non-alcoholic Fatty Liver Disease & NASH Market Analysis
5.1 Global Market Overview
5.2 Global Market Estimation & Forecast
5.2.1 Pre-COVID Market Analysis
5.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
5.3 Regional Market Analysis
5.3.1 Pre-COVID Market Analysis
5.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.4 Global Market Breakdown by Disease Cause
5.4.1 Pre-COVID Market Analysis
5.4.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.4.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.5 Global Market Breakdown by Drug Type
5.5.1 Pre-COVID Market Analysis
5.5.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.5.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
5.6 Global Market Breakdown by Sales Channel
5.6.1 Pre-COVID Market Analysis
5.6.2 Market Share Analysis, 2021,2026 & 2031 (%)
5.6.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6 North America Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.1 North America Market Overview
6.2 North America Market Estimation & Forecast
6.2.1 Pre-COVID Market Analysis
6.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
6.3 North America Market Breakdown by Country
6.3.1 Pre-COVID Market Analysis
6.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.4 North America Market Breakdown by Disease Cause
6.4.1 Pre-COVID Market Analysis
6.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.5 North America Market Breakdown by Drug Type
6.5.1 Pre-COVID Market Analysis
6.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.6 North America Market Breakdown by Sales Channel
6.6.1 Pre-COVID Market Analysis
6.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.7 US Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.7.1 US Market Outlook
6.7.2 Pre-COVID Market Analysis
6.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
6.8 Canada Non-alcoholic Fatty Liver Disease & NASH Market Analysis
6.8.1 Canada Market Outlook
6.8.2 Pre-COVID Market Analysis
6.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7 Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.1 Europe Market Overview
7.2 Europe Market Estimation & Forecast
7.2.1 Pre-COVID Market Analysis
7.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
7.3 Europe Market Breakdown by Country
7.3.1 Pre-COVID Market Analysis
7.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.4 Europe Market Breakdown by Disease Cause
7.4.1 Pre-COVID Market Analysis
7.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.5 Europe Market Breakdown by Drug Type
7.5.1 Pre-COVID Market Analysis
7.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.6 Europe Market Breakdown by Sales Channel
7.6.1 Pre-COVID Market Analysis
7.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.7 Germany Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.7.1 Germany Market Outlook
7.7.2 Pre-COVID Market Analysis
7.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.8 UK Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.8.1 UK Market Outlook
7.8.2 Pre-COVID Market Analysis
7.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.9 France Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.9.1 France Market Outlook
7.9.2 Pre-COVID Market Analysis
7.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.10 Italy Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.10.1 Italy Market Outlook
7.10.2 Pre-COVID Market Analysis
7.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.11 Spain Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.11.1 Spain Market Outlook
7.11.2 Pre-COVID Market Analysis
7.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
7.12 Rest of Europe Non-alcoholic Fatty Liver Disease & NASH Market Analysis
7.12.1 Rest of Europe Market Outlook
7.12.2 Pre-COVID Market Analysis
7.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8 Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.1 Asia-Pacific Market Overview
8.2 Asia-Pacific Market Estimation & Forecast
8.2.1 Pre-COVID Market Analysis
8.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
8.3 Asia-Pacific Market Breakdown by Country
8.3.1 Pre-COVID Market Analysis
8.3.2 Market Share Analysis, 2021,2026 & 2031 (%)
8.3.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.4 Asia-Pacific Market Breakdown by Disease Cause
8.4.1 Pre-COVID Market Analysis
8.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.5 Asia-Pacific Market Breakdown by Drug Type
8.5.1 Pre-COVID Market Analysis
8.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.6 Asia-Pacific Market Breakdown by Sales Channel
8.6.1 Pre-COVID Market Analysis
8.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.7 China Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.7.1 China Market Outlook
8.7.2 Pre-COVID Market Analysis
8.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.8 India Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.8.1 India Market Outlook
8.8.2 Pre-COVID Market Analysis
8.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.9 Japan Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.9.1 Japan Market Outlook
8.9.2 Pre-COVID Market Analysis
8.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.10 South Korea Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.10.1 South Korea Market Outlook
8.10.2 Pre-COVID Market Analysis
8.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.11 Australia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.11.1 Australia Market Outlook
8.11.2 Pre-COVID Market Analysis
8.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
8.12 Rest of Asia-Pacific Non-alcoholic Fatty Liver Disease & NASH Market Analysis
8.12.1 Rest of Asia-Pacific Market Outlook
8.12.2 Pre-COVID Market Analysis
8.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9 LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.1 LAMEA Market Overview
9.2 LAMEA Market Estimation & Forecast
9.2.1 Pre-COVID Market Analysis
9.2.2 Post-COVID Market Analysis (V, W, U, L-Shaped Recovery)
9.3 LAMEA Market Breakdown by Country
9.3.1 Pre-COVID Market Analysis
9.3.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.4 LAMEA Market Breakdown by Disease Cause
9.4.1 Pre-COVID Market Analysis
9.4.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.5 LAMEA Market Breakdown by Drug Type
9.5.1 Pre-COVID Market Analysis
9.5.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.6 LAMEA Market Breakdown by Sales Channel
9.6.1 Pre-COVID Market Analysis
9.6.2 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.7 Brazil Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.7.1 Brazil Market Outlook
9.7.2 Pre-COVID Market Analysis
9.7.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.8 Saudi Arabia Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.8.1 Saudi Arabia Market Outlook
9.8.2 Pre-COVID Market Analysis
9.8.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.9 South Africa Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.9.1 South Africa Market Outlook
9.9.2 Pre-COVID Market Analysis
9.9.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.10 Mexico Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.10.1 Mexico Market Outlook
9.10.2 Pre-COVID Market Analysis
9.10.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.11 UAE Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.11.1 UAE Market Outlook
9.11.2 Pre-COVID Market Analysis
9.11.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
9.12 Rest of LAMEA Non-alcoholic Fatty Liver Disease & NASH Market Analysis
9.12.1 Rest of LAMEA Market Outlook
9.12.2 Pre-COVID Market Analysis
9.12.3 Post-COVID Impact Market Analysis (V, W, U, L-Shaped Recovery)
10 Key Company Profiles
10.1 Pfizer Inc Company
10.1.1 Company Snapshot
10.1.2 Company Overview
10.1.3 Company Financial Profile
10.1.4 Company Product Benchmarking
10.1.5 Company Recent Developments
10.2 F. Hoffmann-La Roche Ltd Company
10.2.1 Company Snapshot
10.2.2 Company Overview
10.2.3 Company Financial Profile
10.2.4 Company Product Benchmarking
10.2.5 Company Recent Developments
10.3 Takeda Pharmaceuticals Company
10.3.1 Company Snapshot
10.3.2 Company Overview
10.3.3 Company Financial Profile
10.3.4 Company Product Benchmarking
10.3.5 Company Recent Developments
10.4 Intercept Pharmaceuticals, Inc. Company
10.4.1 Company Snapshot
10.4.2 Company Overview
10.4.3 Company Financial Profile
10.4.4 Company Product Benchmarking
10.5 AstraZeneca Pharmaceuticals Company
10.5.1 Company Snapshot
10.5.2 Company Overview
10.5.3 Company Financial Profile
10.5.4 Company Product Benchmarking
10.5.5 Company Recent Developments
10.6 Novartis Pharmaceutical Company
10.6.1 Company Snapshot
10.6.2 Company Overview
10.6.3 Company Financial Profile
10.6.4 Company Product Benchmarking
10.6.5 Company Recent Developments
10.7 Merck & Co. Company
10.7.1 Company Snapshot
10.7.2 Company Overview
10.7.3 Company Financial Profile
10.7.4 Company Product Benchmarking
10.7.5 Company Recent Developments
10.8 AbbVie Inc Company
10.8.1 Company Snapshot
10.8.2 Company Overview
10.8.3 Company Financial Profile
10.8.4 Company Product Benchmarking
10.8.5 Company Recent Developments
10.9 Gilead Science Inc Company
10.9.1 Company Snapshot
10.9.2 Company Overview
10.9.3 Company Financial Profile
10.9.4 Company Product Benchmarking
10.9.5 Company Recent Developments
10.10 Genfit Biotechnology Company
10.10.1 Company Snapshot
10.10.2 Company Overview
10.10.3 Company Financial Profile
10.10.4 Company Product Benchmarking
10.10.5 Company Recent Developments
10.11 Cardax Inc Pharmaceutical Company
10.11.1 Company Snapshot
10.11.2 Company Overview
10.11.3 Company Financial Profile
10.11.4 Company Product Benchmarking
10.12 Daewoong Co Ltd Company
10.12.1 Company Snapshot
10.12.2 Company Overview
10.12.3 Company Financial Profile
10.12.4 Company Product Benchmarking
10.12.5 Company Recent Developments
10.13 Madrigal Pharmaceuticals, Inc Company
10.13.1 Company Snapshot
10.13.2 Company Overview
10.13.3 Company Product Benchmarking
10.14 Mirum Pharmaceuticals Inc Company
10.14.1 Company Snapshot
10.14.2 Company Overview
10.14.3 Company Recent Developments
10.15 GW Pharmaceuticals Company
10.15.1 Company Snapshot
10.15.2 Company Overview
10.15.3 Company Financial Profile
10.15.4 Company Product Benchmarking
10.15.5 Company Recent Developments
11 Conclusion & Recommendations
11.1.1 Market Share Analysis, 2021,2026 & 2031 (%)
12 Glossary



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 非アルコール性脂肪性肝疾患(NAFLD)・NASHの世界市場2021年-2031年(Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆